Dual blockade of IL‐4 and IL‐13 with dupilumab, an IL‐4Rα antibody, is required to broadly inhibit type 2 inflammation

Background Dupilumab, a fully human monoclonal antibody that binds IL‐4Rα and inhibits signaling of both IL‐4 and IL‐13, has shown efficacy across multiple diseases with underlying type 2 signatures and is approved for treatment of asthma, atopic dermatitis, and chronic sinusitis with nasal polyposi...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Allergy (Copenhagen) Ročník 75; číslo 5; s. 1188 - 1204
Hlavní autoři:	Le Floc’h, Audrey, Allinne, Jeanne, Nagashima, Kirsten, Scott, George, Birchard, Dylan, Asrat, Seblewongel, Bai, Yu, Lim, Wei Keat, Martin, Joel, Huang, Tammy, Potocky, Terra B., Kim, Jee H., Rafique, Ashique, Papadopoulos, Nicholas J., Stahl, Neil, Yancopoulos, George D., Murphy, Andrew J., Sleeman, Matthew A., Orengo, Jamie M.
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Denmark Blackwell Publishing Ltd 01.05.2020 John Wiley and Sons Inc
Témata:	Allergens Allergies Animals Antibodies, Monoclonal, Humanized Asthma Atopic dermatitis Cell culture Chemokines cytokines dupilumab IL‐13 IL‐4 Immunotherapy Infiltration Inflammation Interleukin-13 Interleukin-4 Intranasal administration Leukocytes (eosinophilic) Mice Monoclonal antibodies Original ORIGINAL ARTICLES Phenotypes Polyposis Respiratory function Sinusitis type 2 inflammation IL-4 cytokines IL-13 type 2 inflammation dupilumab
ISSN:	0105-4538, 1398-9995, 1398-9995
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!